Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Диагностика опухолей печени в условиях стационарных и поликлинических учреждений

СПИСОК ИСПОЛЬЗОВАННЫХ ИСТОЧНИКОВ

  1. Гранов А.М. Гемангиомы печени / А.М. Гранов, В.Н. Полысалов // СПб: Гиппократ. 1999. – 172 с.
  2. Лукьянченко А.Б., Медведева Б.М. Современные возможности лучевой диагностики гепатоцеллюлярных аденом // Медицинская визуализация. – 2013. – № 1. – С. 33–43.
  3. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Рак печени (печеночно-клеточный). 2020. http://cr.rosminzdrav.ru/#!/recomend/709.
  4. Митьков В.В. Практическое руководство по ультразвуковой диагностике. Общая ультразвуковая диагностика 3-е изд перераб. и доп / В.В. Митьков // М.: Издательский дом Видар-М, 2019. — 756 с.
  5. Применение системы LI-RADS в диагностике очаговых изменений печени : методические рекомендации / сост. А. Е. Николаев, А. Н. Шапиев, А. П. Гончар [и др.] // Серия «Лучшие практики лучевой и инструментальной диагностики». – Вып. 32. – М. : ГБУЗ «НПКЦ ДиТ ДЗМ», 2019. – 32 с.
  6. Прокоп М. Спиральная и многослойная компьютерная томография. Учебное пособие в 2-х томах. Пер. с англ. под ред. А.В. Зубарева, Ш.Ш. Шотемора. / М. Прокоп, М. Галански // «МЕДпресс-информ». Москва.: – 2007. –Т.2. – С. 197-269, 416.
  7. Синицын В.Е. Методические рекомендации по безопасному и эффективному использованию контрастных веществ в лучевой диагностике: Российское общество рентгенологов и радиологов – проект, 3-я версия / В.Е. Синицын, И.Е. Тюрин, Т.В. Латышоват // М, 2016.
  8. Труфанов Г. Е. Практическая ультразвуковая диагностика: руководство для врачей: в 5 т. Т. 1. Ультразвуковая диагностика заболеваний органов брюшной полости / Г.Е. Труфанов, В.В. Рязанова // Москва: ГЭОТАР-Медиа. - 2016. – 240 с.
  9. Хомерики С.Г. Билиарный папилломатоз: трудности дифференциальной диагностики / С.Г. Хомерики // Доказательная медицина 2014. – Т.3. – №1. – С. 20-26.
  10. ACG clinical guideline: the diagnosis and management of focal liver lesions. / J.A. Marrero, J. Ahn, R.K. Reddy et al. // Am J Gastroenterol, 2014. – Vol. 109, №9. – P. 1328-1348.
  11. ACR Manual on Contrast Media Davenport / S.J. Cavallo, R. Cohan et al. // ACR Committee on Drugs and Contrast Media. Version 10.3. – 2018.
  12. Benign focal liver lesions detected by computed tomography. Review of 1,184 examinations. / G. Horta, M. López, A. Dotte et al. // Revista médica de Chile, 2015. – Vol. 143, №2. – P. 197–202.
  13. Bosman F.T. WHO Classification of Tumours of the Digestive System 4 th edition. / F.T. Bosman, F. Carneiro, R.H. Hruban et al. // Lion: IARC Press, 2010. – P. 417.
  14. Campos J. Focal Hepatic Lesions in Gd-EOB-DTPA Enhanced MRI: The Atlas. / J. Campos, C. Sirlin, J. // Choi Insights Imaging. 2012. – Vol.3, №5. – P. 451-74.
  15. Cavernous hemangiomas of the liver: are there any indications for resection / O. Farges, S. Daradkeh, H. Bismuth et al. // World journal of surgery, 1995. – Vol. 19, №1. – P. 19–24.
  16. Changing trends in malignant transformation of hepatocellular adenoma. / O. Farges, N. Ferreira, S. Dokmak et al. Gut, 2011 – Vol. 60. – P. 85–89.
  17. Cholangiocarcinoma - evolving concepts and therapeutic strategies. / S. Rizvi, S.A. Khan, C.L. Hallemeier et al. // Nat Rev Clin Oncol, 2018. – Vol. 15, №2. – P. 95-111.
  18. Detection and characterization of focal hepatic lesions with diffusion-weighted MR imaging a pictorial review. / M. Kanematsu, S. Goshima, H. Watanabe et al. // Abdom Imaging, 2013. – Vol. 38, №2. – P. 297-308.
  19. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. / J.A. Marrero, L.M. Kulik, C.B. Sirlin et al. // Hepatology, 2018. – Vol. 68, №2. – P. 723–50.
  20. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. / J.Y. Choi, S.W. Jung, H.Y. Kim et al. // World J Gastroenterol, 2013 – Vol. 19, №3. – P. 339-46.
  21. Effects of liver cirrhosis and patient condition on clinical outcomes in intrahepatic cholangiocarcinoma: a retrospective analysis of 156 cases in a single center. / D. Jesper, S.G. Heyn, B. Schellhaas et al. // Eur J Gastroenterol Hepatol, 2018. – Vol. 30. – P. 552–556.
  22. ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. / A. Vogel, A. Cervantes, I. Chau et al. // Ann Oncol, 2018. – Vol. 1, №29, S4. Erratum in: Ann Oncol, 2022. – Vol. 33, №6. – P. 666.
  23. European Association for the Study of the Liver. Clinical Practice Guidelines on the management of benign liver tumours. / М. Colombo, A. Forner, J. Ijzerman et al. // Journal of hepatology, 2016 – Vol. 65, №2. – P. 386–398.
  24. European Association for the Study of the Liver. Сlinical practice guidelines: management of hepatocellular carcinoma. / P.R. Galle, A. Forner, J.M. Llovet et al. // J Hepatol, 2018. – Vol. 69, №1. – P.182-236.
  25. Evaluation of the Combined Application of AFP, AFP-L3, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis. / X. Wang, Y. Zhang, N. Yang et аl. // Biomed Res Int, 2020. – Vol. 17. - 5087643.
  26. Fluid–fluid Level in Hepatic Metastases: A Characteristic Sign of Metastases of Neuroendocrine Origin. / W. Sommer, C. Zech, F. Bamberg et al. // Eur J Radiol, 2012. – Vol. 81, №9. – P. 2127-32.
  27. Focal Liver Lesions: Detection, Characterization, Ablation. / A.L. Baert, R. Lencioni, D. Cioni et al. // Diagnostic Imaging. Medical Radiology. Springer, 2005. – P. 403.
  28. Focal Nodular Hyperplasia and Hepatocellular Adenoma: Accuracy of Gadoxetic Acid– enhanced MR Imaging—A Systematic Review. / M. McInnes, R. Hibbert, J. Inácio et al. // Radiology, 2015. – Vol. 277, №3. – P. 927.
  29. Focal nodular hyperplasia of the liver in 86 patients. / Y.H. Shen, J. Fan, Z.Q. Wu et al. // Hepatobiliary Pancreat. Dis. Int, 2007. – Vol. 6. – P. 52 – 57.
  30. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. / B.N. Nguyen, J.F. Flejou, B. Terris et al. // Am. J. Surg. Pathol, 1999. – Vol. 23. – P. 1441–1454.
  31. Focal Nodular Hyperplasia: Findings at State-of-the-Art MR Imaging, US, CT, and Pathologic Analisis / S.M. Hussain, T. Terkivatan, P. Zondervan, et al. // RadioGraphics, 2004. – Vol. 24, №1. – P. 3–17.
  32. Gadolinium contrast agent selection and optimal use for body MR imaging. / F.F. Guglielmo, D.G. Mitchell, S. Gupta et al. // Radiol. Clin. North Am, 2014 – Vol. 52, №4. – P. 637-56.
  33. gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf
  34. Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS) in the liver update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. / M. Claudon, C.F. Dietrich, B.I. Choi et al. // Ultraschall Med, 2013 – Vol.34, №1. – P.11-29.
  35. Guindi M. So-Called Telangiectatic Focal Nodular Hyperplasia A Newly Recognized Variant of Hepatic Adenoma. / M. Guindi // Pathology Case Reviews, 2007. – Vol. 12. – P. 154 – 159.
  36. Hall G.W. Kasabach–Merritt syndrome: pathogenesis and management. / G.W. Hall // British journal of haematology, 2001. – Vol. 112, №4. – P. 851–862.
  37. Hepatic Adenoma. / S. Faria, R. Iyer, A. Rashid et al. // AJR Am J Roentgenol, 2004. – Vol. 182, №6. – P. 1520.
  38. Hepatic Adenomas: Imaging and Pathologic Findings. / L. Grazioli, M. Federle, G. Brancatelli // Radiographics, 2001. – Vol. 21, №4. – P. 877-92.
  39. Hepatic arterioportal shunts: dynamic CT and MR features. / B.I. Choi, K.H. Lee, J.K. Han et al. // Korean J Radiol, 2002. – Vol.3, №1. – P. 1-15.
  40. Hepatic cavernous hemangioma: underrecognized associated histologic features / G.E. Kim, S.N. Thung, W.M. Tsui et al. // Liver International, 2006. – Vol. 26, №3. – P. 334– 338.
  41. Hepatic haemangiomas: possible association with female sex hormones. / V. Glinkova, O. Shevah, M. Boaz // Gut, 2004. – Vol. 53, №9. – P. 1352–1355.
  42. Hepatocellular Adenoma and Focal Nodular Hyperplasia: Value of Gadoxetic Acid–enhanced MR Imaging in Differential Diagnosis. / L. Grazioli, M. Bondioni, H. Haradome et al. // Radiology, 2012. – Vol. 262, №2. – P. 520-9.
  43. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. / S. Chidambaranathan-Reghupaty, P.B. Fisher, D. Sarkar // Adv Cancer Res, 2021. – Vol.149. – P.1-61.
  44. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. / N.M. Tunissiolli, M.M.U. Castanhole-Nunes, P.M. Biselli-Chicote et al. // Asian Pac J Cancer Prev, 2017. – Vol. 18, №4. – P. 863-872.
  45. Histological classification of liver and intrahepatic bile duct cancers in SEER registries. / S.F. Altekruse, S.S. Devesa, L.A. Dickie et al. // J Registry Manag, 2011. – Vol. 38, №4. – P. 201-205.
  46. Histological Grading of Hepatocellular Carcinoma-A Systematic Review of Literature. / S.N. Martins-Filho, C. Paiva, R.S. Azevedo et al. // Front Med (Lausanne), 2017. – Vol. 4. – P. 193.
  47. Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. / J.M. Willatt, H.K. Hussain, S. Adusumilli et аl. // Radiology, 2008. – Vol. 247, №2. – P. 311-30.
  48. Infiltrative hepatocellular carcinoma: what radiologists need to know. / A.R. Reynolds, A. Furlan, D.T. Fetzer et al. // Radiographics, 2015. – Vol. 35, №2. – P. 371-86.
  49. International Working Party. Terminology of nodular hepatocellular lesions. / I.R. Wanless, F. Callea, J.R. Craig et al. // Hepatology, 1995. – Vol. 22. – P. 983 - 993.
  50. Intraarterial and intravenous contrast enhanced CT and MR imaging of multi-step hepatocarcinogenesis defining the early stage of hepatocellular carcinoma development. / S. Kobayashi, K. Kozaka, T. Gabata et al. // Hepatoma Res, 2020 – Vol. 6. – P. 36.
  51. Intrahepatic Mass-forming Cholangiocarcinoma: Arterial Enhancement Patterns at MRI and Prognosis. / J.H. Min, Y.K. Kim, S.-Y. Kim et al. // Radiology, 2019. – Vol. 290, №3. – P. 691-699.
  52. Intratumoral Steatosis in Focal Nodular Hyperplasia Coinciding with Diffuse Hepatic Steatosis: CT and MRI Findings with Histologic Correlation. / K. Mortelé, J. Stubbe, M. Praet et al. // Abdom Imaging, 2000. – Vol. 25, №2. - P. 179-81.
  53. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma. / H.A. Lee, Y.R. Lee, Y.S. Lee et al. // World J Gastroenterol, 2021. – Vol. 28, №27. - P. 4687-4696.
  54. Lincke T. Liver metastases: Detection and staging. / T. Lincke, C.J. Zech // Eur J Radiol, 2017. – Vol. 97. – P. 76-82.
  55. Malhi H. Contrast-Enhanced Ultrasound of the Liver and Kidney. / H. Malhi, E. Grant, V. Duddalwar // Radiol Clin North Am, 2014. – Vol. 52, №6. – P. 1177-1190.
  56. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. / J.H. Stoot, R.J. Coelen, M.C. De Jong et al. // HPB (Oxford), 2010. – Vol. 12, №8. – P. 509-22.
  57. Massarweh N.N. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. / N.N. Massarweh, H.B. El-Serag // Cancer Control, 2017. – Vol. 24, №3. - 1073274817729245.
  58. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. / J.C. Nault, G. Couchy, C. Balabaud et al. // Gastroenterology, 2017. – Vol. 152, №4. – P. 880-94.
  59. MR Imaging of Hepatocellular Adenomas and Differential Diagnosis Dilemma. / L. Grazioli, L. Olivetti, G. Mazza et al. // Int J Hepatol, 2013. – 374170. – P. 1–20.
  60. MRI features of hepatocellular carcinoma related to biologic behavior. / E.S. Cho, J.Y. Choi // Korean journal of radiology, 2015. – Vol.16, №3. – P. 449-64.
  61. Multiple hepatic sclerosing hemangioma mimicking metastatic liver tumor successfully treated by laparoscopic surgery: report of a case. / M. Wakasugi, S. Ueshima, M. Tei // International journal of surgery case reports, 2015. – Vol. 8. – P. 137–140.
  62. Namasivayam S. Imaging of Liver Metastases: MRI. / S. Namasivayam // Cancer Imaging, 2007. – Vol. 7, №1. – P. 2-9.
  63. Palmucci S. Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI. / S. Palmucci // World J Hepatol, 2014. – Vol. 6, №7. – P. 477- 485.
  64. Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. / H.L.Y. Chan, A. Vogel, T. Berg et al. // JGH Open, 2022. – Vol.6, №5. – P. 292-300.
  65. Qayyum A. Diffusion-Weighted Imaging in the Abdomen and Pelvis: Concepts and Applications. / A. Qayyum // Radiographics, 2009. – Vol. 29, №6. – P. 1797-810.
  66. Semelka R.C. Abdominal-Pelvic MRI. / R.C. Semelka // John Wiley & Sons Inc, 2005. – P. 1477.
  67. Sex hormones and risk of liver tumor / L. Giannitrapani, M. Soresi, E.L. Spada, et al. / / Annals of the New York Academy of Sciences, 2006. – Vol. 1089, №1. – P. 228–236.
  68. SIUMB guidelines and recommendations for the correct use of ultrasound in the management of patients with focal liver disease. / G. Vidili, I. De Sio, M. D'Onofrio et al. // Journal of ultrasound, 2019. – Vol. 22, №1. – P. 41–51.
  69. Surveillance imaging and alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. / K. Tzartzeva, J. Obi, N.E. Rich et al. // Gastroenterology, 2018. – Vol. 154. – P. 1706–1718.
  70. System Liver Imaging Reporting And Data System – LI-RADS [American College of Radiology. – URL: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018.
  71. Torbenson M.S. Morphologic Subtypes of Hepatocellular Carcinoma. / M.S. Torbenson // Gastroenterol Clin North Am, 2017. – Vol. 46. – P. 365-391.
  72. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. / D.F. Hayes, R.C. Bast, C.E. Desch et al. // J Natl Cancer Inst 1996, – P.1456– 1466.
  73. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. / R.K. Sterling, L. Jeffers, F. Gordon et al. // Clin Gastroenterol Hepatol, 2009. – Vol. 7. P. 104–113.
  74. Van Beers B.E. Primovist, Eovist: what to expect? / B.E. Van Beers, C.M. Pastor, H.K. Hussain // J Hepatol, 2012. – Vol. 57, №2. – P. 421-429.
  75. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. / Y.E. Chung, M.J. Kim, Y.N. Park et al. // Radiographics, 2009. - Vol.29, №3. – P. 683-700.
  76. Wanless I.R. On the pathogenesis of focal nodular hyperplasia of the liver / I.R. Wanless, C. Mawdsley, R. Adams // Hepatology, 1985. – Vol. 5. – P. 1194 - 1200.
  77. Приказа Департамента здравоохранения города Москвы от 14.01.2022 № 16 «Об организации оказания медицинской помощи по профилю «онкология» в медицинских организациях государственной системы здравоохранения города Москвы»

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
СПИСОК ИСПОЛЬЗОВАННЫХ ИСТОЧНИКОВ
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*